Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2025 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day ...
October 08, 2025 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to...
October 06, 2025 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit

SAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
September 04, 2025 07:00 ET | Source: GT Biopharma, Inc.

GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory...
August 11, 2025 07:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues...
June 13, 2025 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Appoints New Member to its Board of Directors

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
May 19, 2025 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed...
May 15, 2025 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Appoints New Member to its Board of Directors

SAN FRANCISCO, CALIFORNIA, May 15, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
May 14, 2025 07:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Appoints New Member to its Board of Directors

SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
March 04, 2025 07:00 ET | Source: GT Biopharma, Inc.

GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit

SAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...